|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
adults
combination drug
adolescents (12 years and older)
|
|
gptkbp:alsoKnownAs
|
gptkb:REGEN-COV
gptkb:casirivimab/imdevimab
|
|
gptkbp:approvedBy
|
gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency
gptkb:European_Medicines_Agency
gptkb:Japan_Ministry_of_Health,_Labour_and_Welfare
2021
|
|
gptkbp:ATCCode
|
gptkb:J06BD08
|
|
gptkbp:contains
|
gptkb:casirivimab
gptkb:imdevimab
|
|
gptkbp:developedBy
|
gptkb:Regeneron_Pharmaceuticals
gptkb:Roche
|
|
gptkbp:emergencyServices
|
gptkb:US_FDA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ronapreve
|
|
gptkbp:indication
|
mild to moderate COVID-19
post-exposure prophylaxis of COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to SARS-CoV-2 spike protein
blocks virus entry into human cells
|
|
gptkbp:notRecommendedFor
|
hospitalized patients requiring oxygen
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
antibody cocktail
|
|
gptkbp:usedFor
|
gptkb:COVID-19
COVID-19 prevention
|
|
gptkbp:WHOStatus
|
recommended for certain COVID-19 patients
|
|
gptkbp:bfsParent
|
gptkb:Roche_Holding_AG
gptkb:REGEN-COV_(casirivimab_and_imdevimab)
gptkb:Hoffmann-La_Roche
|
|
gptkbp:bfsLayer
|
7
|